

Treatment of relapsed and refractory multiple myeloma

The HDAC inhibitors panobinostat and vorinostat are epigenetic drugs that can be combined with other agents.

Panobinostat had a significant advantage when combined with bortezomib and dexamethasone over the same drugs with placebo; at the cost, however, of gastrointestinal symptoms and fatigue. Panobinostat combined with bortezomib and dexamethasone has been approved by the EMA for use in RRMM patients.

Pieter Sonneveld¹ and Annemiek Broijl²

¹University Hospital Rotterdam; ²ErasmusMC Cancer Institute, The Netherlands

*Correspondence: p.sonneveld@erasmusmc.nl
doi:10.3324/haematol.2016.148882*

Key words: multiple myeloma, chemotherapy, immunotherapy, relapse.

Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.